Share on StockTwits
 

Seattle Genetics (NASDAQ:SGEN) CMO Jonathan G. Drachman sold 1,201 shares of Seattle Genetics stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $45.75, for a total value of $54,945.75. Following the sale, the chief marketing officer now directly owns 49,911 shares in the company, valued at approximately $2,283,428. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on SGEN shares. Analysts at RBC Capital raised their price target on shares of Seattle Genetics from $44.00 to $48.00 in a research note to investors on Friday, December 20th. Analysts at Piper Jaffray reiterated an “underweight” rating on shares of Seattle Genetics in a research note to investors on Monday, December 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Seattle Genetics presently has a consensus rating of “Hold” and an average price target of $42.24.

Seattle Genetics (NASDAQ:SGEN) remained flat at $47.95 during during mid-day trading trading on Tuesday. 1,047,898 shares of the company’s stock traded hands. Seattle Genetics has a 52 week low of $26.60 and a 52 week high of $49.45. The stock has a 50-day moving average of $41.46 and a 200-day moving average of $41.58. The company’s market cap is $5.873 billion.

Seattle Genetics (NASDAQ:SGEN) last released its earnings data on Tuesday, November 5th. The company reported ($0.19) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.22) by $0.03. The company had revenue of $71.00 million for the quarter, compared to the consensus estimate of $57.79 million. During the same quarter last year, the company posted ($0.12) earnings per share. Seattle Genetics’s revenue was up 42.5% compared to the same quarter last year. On average, analysts predict that Seattle Genetics will post $-0.63 earnings per share for the current fiscal year.

Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.